ClinicalTrials.gg
CompletedNCT02456883Updated Nov 5, 2024

Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of gilteritinib and 14C-labeled gilteritinib in Advanced Solid Tumors and Pharmacokinetics of 14C-labeled Gilteritinib, sponsored by Astellas Pharma Global Development, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics of 14C-labeled gilteritinib, in particular, the routes of excretion and extent of metabolism of gilteritinib following administration of a single dose of 14C-labeled gilteritinib after repeated doses of gilteritinib.

This study will also evaluate the safety of repeated oral administration of gilteritinib in subjects with advanced solid tumors as well as identify the metabolic profile of gilteritinib in plasma, urine and feces after a single oral dose of 14C-labeled gilteritinib.

Read the detailed description

Participants will be admitted for evaluation to the clinical research unit on day 14 for potentially up to 14 days (day 29). At approximately days 36 and 45 participants will return to the clinic (for 3 days) for additional sample collection.

02

Conditions studied

  • Advanced Solid Tumors
  • Pharmacokinetics of 14C-labeled Gilteritinib

Keywords

  • ASP2215
  • 14C-labeled gilteritinib
  • Advanced Solid Tumors
  • Pharmacokinetics
  • gilteritinib
03

In context

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject had or cytologically confirmed diagnosis of advanced solid tumor (measurable or nonmeasurable disease) for which no standard therapy is available.
  • Subject must have an (ECOG) performance status ≤ 1.
  • Subject must have a > 12 weeks.
  • Subject must have recovered from the effects of prior systemic antineoplastic or radiation therapy(s) to ≤ Grade 1 (National Cancer Institute - [NCI-CTCAE], Version 4.0) severity or to subject's baseline values, excluding alopecia.
  • Subject has adequate bone marrow, renal and hepatic function at baseline, as demonstrated by the following:

    • (ANC) ≥ 1500 cells/mm3
    • count ≥ 100,000 cells/mm3
    • (Hb) ≥ 9 g/dL
    • Serum creatinine ≤ 1.5 x (ULN) or calculated > 60 mL/min if the serum creatinine is > 1.5 x ULN
    • Total ≤ 1.5 x ULN
    • (AST) or alanine aminotransferase (ALT) ≤ 3 x ULN (or \< 5 x ULN in subjects with liver or hepatocellular carcinoma).
  • Female subject must either:

    • Be of nonchildbearing potential: (defined as at least 1 year without any menses) prior to screening, or documented surgically sterile
    • Or, if of : agree not to try to become pregnant during the study and for 60 days after the final study drug administration and have a negative serum or urine pregnancy test at screening, and if heterosexually active, agree to consistently use 2 forms of (at least one of which must be a barrier method) starting at screening and throughout the study period and for 60 days after final study drug administration.
  • Female subject must not be breastfeeding at screening or during the study period, and for 60 days after the final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the study period and for 60 days after final study drug administration.
  • Male subject and a female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (one of which must be a barrier method) starting at screening and continue throughout the study period and for 120 days after the final study drug administration.
  • Male subject must not donate sperm starting at screening and throughout the study period and for 120 days after final study drug administration.
  • Subject must be willing to comply with all procedures and assessments.

Exclusion criteria

Exclusion Criteria:

  • Subject has received more than 5 prior cytotoxic agent-containing regimens.
  • Subject has symptomatic central nervous system (CNS) or as assessed through medical history review and physical examination. Subject with prior must:

    • have stable neurologic status post administration of local therapy (surgery or radiation) for a minimum of 2 weeks following completion of the definitive therapy.
    • be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs).
  • Subject has had major surgery within 4 weeks prior to the first study dose.
  • Subject has had chemotherapy within 4 weeks prior to the first study dose.
  • Subject has had radiation therapy within 4 weeks prior to the first study dose.
  • Subject with known surface antigen (HBsAg) positive status; or known or suspected active infection; or known (HIV) positive.
  • Subject with malabsorption syndrome or disease or condition significantly affecting gastrointestinal function.
  • Subject with significant or uncontrolled cardiac, renal, hepatic or other systemic disorders; or significant psychological conditions at baseline that in the investigator's opinion, makes the subject unsuitable for study participation.
  • Subject with (ECG) abnormalities on a 12-lead ECG performed within 14 days before start of the study drug that are considered by the Investigator to be .
  • Subject who has received strong or moderate inhibitors (e.g., ketoconazole or fluconazole) or inducers (e.g., rifampin or phenytoin) of cytochrome P450 (CYP)3A4 or of P-glycoprotein (P-gp), or substrates of multidrug and toxin extrusion (MATE)1 with the exception of antibiotics, antifungals, and antivirals that are used as standard of care post transplant or to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the subject within 2 weeks prior to start of study treatment and while on study.
  • Subject requires treatment with concomitant drugs that target serotonin 5HT1R or 5HT2BR receptors or sigma nonspecific receptor, with the exception of drugs that are considered absolutely essential for the care of the subject.
  • Subject has participated in any interventional clinical study or has been treated with any drugs within 30 days or 5 half-lives, whichever is longer, prior to the initiation of screening.
  • Subject has a known history of serious to ASP2215, or any component of the formulation used.
  • Subject who has an ongoing toxicity ≥ Grade 2 (Common Terminology Criteria for Adverse Event [] v4.03) attributable to prior medication to treat solid tumor (except alopecia) at the time of screening.
  • Subject has had any of the following within 14 days prior to the first dose of study drug:

    • blood transfusion or hemopoietic factor therapy
    • evidence of active infection requiring systemic therapy.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    gilteritinib and 14C-labeled gilteritinib

    Gilteritinib will be taken once daily on study days 1 through 14 and days 16 through 47. On day 15, each participant will be given a single dose of 14C-labeled gilteritinib.

    Drug: gilteritinib · Drug: 14C-labeled gilteritinib

Interventions

  • oral

    Also known as: ASP2215

  • Drug14C-labeled gilteritinib

    oral

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in whole blood): AUCtau

    Area under the concentration curve over the dosing interval (AUCtau)

    Time frame: Days 15 - 46

  2. Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in whole blood): Cmax

    Maximum concentration (Cmax)

    Time frame: Days 15 - 46

  3. Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in whole blood): tmax

    Time of maximum concentration (tmax)

    Time frame: Days 15 - 46

  4. Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in whole blood): t1/2

    Terminal elimination half-life (t1/2)

    Time frame: Days 15 - 46

  5. Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in whole blood): CL/F

    Apparent body clearance after extravascular dosing (CL/F)

    Time frame: Days 15 - 46

  6. Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in plasma): AUCtau

    Time frame: Days 15 - 46

  7. Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in plasma): Cmax

    Time frame: Days 15 - 46

  8. Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in plasma): tmax

    Time frame: Days 15 - 46

  9. Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in plasma): t1/2

    Time frame: Days 15 - 46

  10. Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity in plasma): CL/F

    Time frame: Days 15 - 46

  11. Pharmacokinetics of 14C-labeled gilteritinib (Radioactivity ratio of whole blood/plasma concentrations): AUC

    Area under the concentration (AUC)

    Time frame: Days 15 - 46

  12. Excretion rate of 14C-labeled gilteritinib (radioactivity in urine)

    Percent of dose excreted in urine

    Time frame: Days 15 - 46

  13. Cumulative excretion of 14C-labeled gilteritinib (radioactivity in urine)

    Cumulative total of radioactivity excreted in urine

    Time frame: Days 15 - 46

  14. Excretion rate of 14C-labeled gilteritinib (radioactivity in feces)

    Percent of dose excreted in feces

    Time frame: Days 15 - 46

  15. Cumulative excretion of 14C-labeled gilteritinib (radioactivity in feces)

    Cumulative total of radioactivity excreted in feces

    Time frame: Days 15 - 46

  16. Pharmacokinetics of gilteritinib (in plasma): AUCtau

    Time frame: Days 15 - 46

  17. Pharmacokinetics of gilteritinib (in plasma): Cmax

    Time frame: Days 15 - 46

  18. Pharmacokinetics of gilteritinib (in plasma): tmax

    Time frame: Days 15 - 46

  19. Pharmacokinetics of gilteritinib (in plasma): CL/F

    Time frame: Days 15 - 46

  20. Pharmacokinetics of gilteritinib (in urine): Aetau

    Cumulative amount of study drug excreted into urine from the time of dosing to the start of the next dosing interval (Aetau)

    Time frame: Days 15 - 46

  21. Pharmacokinetics of gilteritinib (in urine): CLR

    Renal clearance (CLR)

    Time frame: Days 15 - 46

  22. Pharmacokinetics of gilteritinib (in urine): AETAU%

    Percentage of study drug dose excreted into urine over the time interval between consecutive dosing (AETAU%)

    Time frame: Days 15 - 46

Secondary outcomes

  1. Metabolite identification of gilteritinib in plasma, urine and feces

    Time frame: Days 15 - 46

07

Study locations

1 site
  • Site US10001
    Cleveland, Ohio 44195, United States
08

References and documents

Publications

  • James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clin Pharmacokinet. 2020 Oct;59(10):1273-1290. doi: 10.1007/s40262-020-00888-w. Erratum In: Clin Pharmacokinet. 2021 Sep;60(9):1251. doi: 10.1007/s40262-021-01060-8. PubMed 32304015 ↗

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in May 2017, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2015
First posted
May 29, 2015
StartActual
Mar 4, 2016
Primary completionActual
May 20, 2017
CompletionActual
Jun 19, 2017
Last update
Nov 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02456883
Responsible party
Sponsor
First posted
May 29, 2015
Start date
Mar 4, 2016
Primary completion
May 20, 2017
Completion
Jun 19, 2017
Last update
Nov 5, 2024

Study contacts

Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gilteritinib

Start the discussion